AVIL: A Technology for Disease Detection and Monitoring (G10677)

Target Name: AVIL

NCBI ID: G10677

AVIL

AVIL: A Technology for Disease Detection and Monitoring

AVIL (short for Autonomous Video Image Recognition) is a technology developed by the research company Natera that uses machine learning algorithms to analyze and identify patterns in video images. This technology has the potential to be a drug target or biomarker in the medical field, as it can be used to detect and track a variety of health conditions, including cancer, heart disease, and neurological disorders.

One of the key benefits of AVIL is its ability to detect and track changes in the body over time. This can be especially important for diseases that are difficult to diagnose or monitor, such as cancer. By analyzing a person's video images over time, AVIL can identify any changes in their body that may indicate the presence of a cancerous growth. This could allow doctors to take action early on, such as performing a biopsy or starting treatment, which can significantly improve treatment outcomes.

In addition to its ability to detect cancer, AVIL also has the potential to be used as a biomarker for other diseases. For example, it can be used to track the progression of heart disease by analyzing a person's video images over time. This can help doctors identify any changes in the body that may indicate the presence of a heart condition, such as a heart attack, and take action early on.

AVIL has the potential to be used as a drug target as well. By analyzing a person's video images, doctors can identify any patterns in their body that may indicate the presence of a specific disease or condition. This could allow doctors to develop new treatments or drug candidates that are tailored to the individual's unique needs.

In addition to its potential as a drug target or biomarker, AVIL also has a wide range of other potential applications in the medical field. For example, it can be used to monitor the effectiveness of treatments by analyzing a person's video images before and after treatment. This can help doctors determine if a treatment is having the desired effect and make any necessary adjustments.

Overall, AVIL has the potential to be a significant tool in the fight against disease. Its ability to detect and track changes in the body over time, as well as its potential as a drug target or biomarker, makes it an exciting area of research with the potential to improve the lives of people around the world.

Protein Name: Advillin

Functions: Ca(2+)-regulated actin-binding protein which plays an important role in actin bundling (PubMed:29058690). May have a unique function in the morphogenesis of neuronal cells which form ganglia. Required for SREC1-mediated regulation of neurite-like outgrowth. Plays a role in regenerative sensory axon outgrowth and remodeling processes after peripheral injury in neonates. Involved in the formation of long fine actin-containing filopodia-like structures in fibroblast. Plays a role in ciliogenesis. In podocytes, controls lamellipodia formation through the regulation of EGF-induced diacylglycerol generation by PLCE1 and ARP2/3 complex assembly (PubMed:29058690)

The "AVIL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AVIL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets